Cipla Gets Final Approval For Generic Version Of Revlimid

NEW YORK CITY (dpa-AFX) - Cipla Limited has received final approval for its Abbreviated New Drug Application for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the FDA. Cipla's Lenalidomide

Related Keywords

Bristol Myers Squibb Revlimid ,Cipla ,More Such Health News ,Abbreviated New Drug Application ,Lenalidomide Capsule ,Lenalidomide Capsules ,Bristol Myers Squibb ,Multiple Myeloma ,Marginal Zone ,Jets ,Final ,Approval ,Generic ,Version ,Revlimid ,